ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
ABNX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012616852 (+1 more)
- LEI:
- 969500785J7VIC5YPC96
- Country:
- France
- Address:
- 33 AVENUE GEORGES POMPIDOU, 31130 BALMA
- Website:
- https://abionyx.com/en/
- Sector:
- Manufacturing
Description
ABIONYX Pharma is a new-generation biotechnology company that develops innovative therapies for indications with no effective or existing treatments. The company leverages extensive expertise in lipid metabolism and is a leader in recombinant apolipoprotein A-I (apoA-I), the primary protein of High-Density Lipoprotein (HDL). Its core technology platform utilizes apoA-I to create novel biotherapies and HDL vectors for targeted drug delivery. Key therapeutic areas of focus include critical illnesses such as sepsis, as well as renal and ophthalmological diseases. The company's strategy involves an integrated approach, combining biotherapy with diagnostics to address complex medical conditions with high unmet needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-01-24 19:17 |
Communiqués au titre de l'obligation d'information permanente / Information sur…
|
French | 302.1 KB | ||
| 2019-01-23 18:25 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 157.8 KB | ||
| 2019-01-23 18:25 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 161.8 KB | ||
| 2019-01-11 18:19 |
Rachat d'actions / Contrat de liquidité Information relative au contrat de liqu…
|
French | 150.7 KB | ||
| 2019-01-11 18:19 |
Share buybacks / Liquidity contracts Information related to liquidity contrac…
|
English | 187.9 KB | ||
| 2019-01-11 18:07 |
Information relating to the total number of voting rights and shares making up …
|
English | 168.1 KB | ||
| 2019-01-11 18:07 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 171.6 KB | ||
| 2018-12-20 19:38 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 414.3 KB | ||
| 2018-12-20 19:38 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 420.7 KB | ||
| 2018-12-19 07:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 454.7 KB | ||
| 2018-12-19 07:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 456.9 KB | ||
| 2018-12-17 18:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 292.4 KB | ||
| 2018-12-17 18:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 238.5 KB | ||
| 2018-12-13 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 171.8 KB | ||
| 2018-12-13 18:00 |
Information relating to the total number of voting rights and shares making up …
|
English | 168.2 KB |
Automate Your Workflow. Get a real-time feed of all ABIONYX Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIONYX Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIONYX Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-02-28 | N/A | Other | Buy | 53,913 | N/A |
Peer Companies
